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Abstract
Background: Limited information regarding the clonality of circulating E. coli strains in tertiary care hospitals in low
and middle-income countries is available. The purpose of this study was to determine the serotypes, antimicrobial
resistance and virulence genes. Further, we carried out a phylogenetic tree reconstruction to determine relatedness
of E. coli isolated from patients in a tertiary care hospital in Tanzania.
Methods: E. coli isolates from inpatients admitted at Kilimanjaro Christian Medical Centre between August 2013
and August 2015 were fully genome-sequenced at KCMC hospital. Sequence analysis was done for identification of
resistance genes, Multi-Locus Sequence Typing, serotyping, and virulence genes. Phylogeny reconstruction using
CSI Phylogeny was done to ascertain E. coli relatedness. Stata 13 (College Station, Texas 77,845 USA) was used to
determine Cohen’s kappa coefficient of agreement between the phenotypically tested and whole genome
sequence predicted antimicrobial resistance.
Results: Out of 38 E. coli isolates, 21 different sequence types (ST) were observed. Eight (21.1%) isolates belonged
to ST131; of which 7 (87.5.%) were serotype O25:H4. Ten (18.4%) isolates belonged to ST10 clonal complex; of these,
four (40.0%) were ST617 with serotype O89:H10. Twenty-eight (73.7%) isolates carried genes encoding beta-lactam
resistance enzymes. On average, agreement across all drugs tested was 83.9%. Trimethoprim/sulphamethoxazole
(co-trimoxazole) showed moderate agreement: 45.8%, kappa =15% and p = 0.08. Amoxicillin-clavulanate showed
strongest agreement: 87.5%, kappa = 74% and p = 0.0001. Twenty-two (57.9%) isolates carried virulence factors for
host cells adherence and 25 (65.7%) for factors that promote E. coli immune evasion by increasing survival in serum.
The phylogeny analysis showed that ST131 clustering close together whereas ST10 clonal complex had a very clear
segregation of the ST617 and a mix of the rest STs.
Conclusion: There is a high diversity of E. coli isolated from patients admitted to a tertiary care hospital in Tanzania.
This underscores the necessity to routinely screen all bacterial isolates of clinical importance in tertiary health care
facilities. WGS use for laboratory-based surveillance can be an effective early warning system for emerging
pathogens and resistance mechanisms in LMICs.
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Background
Escherichia coli are Gram-negative bacterial commensals
that naturally inhabit the human gastrointestinal tract
(GIT). Through horizontal transfer and other mecha-
nisms, commensal E. coli regularly acquire virulence,
pathogenicity and multi-drug resistance properties from
pathogenic E. coli. Consequently, E. coli is an important
causative agent for a range of nosocomial and opportunis-
tic infections including neonatal meningitis, diarrhoea,
septicaemia, urinary tract and wound infections [1–5].
The global emergence and spread of multidrug resistant
(MDR) E. coli in both community and as nosocomial in-
fections, as well as in animals, warrants public health con-
cerns [6–9]. Furthermore, virulent E. coli strains share
resistance, virulence and pathogenic factors with avirulent
or less virulent strains, enabling them to cause overlapping
pathogenesis beyond their classical capacities [10]. Several
E. coli outbreaks leading to serious health, social and
economic impacts have been reported in high income
countries (HICs) including the Netherlands [11], the UK
[12], Norway, and Georgia [10].
Africa is highly burdened by diarrhoea and urinary
tract infections (UTIs) that are E. coli related. For in-
stance, in rural Kenya it was reported that 64.5% of UTI
or bacteriuria was E. coli related [13]. In north-western
Tanzania, 41.2 and 70% of UTI or bacteriuria was E. coli
related among under-fives and febrile children, respect-
ively [14, 15]. Similarly, in north-eastern part of
Tanzania, E. coli accounted for 56.1% of all UTI cases
among children [5] and E. coli accounted for 79 and 75%
of UTI in non-malaria febrile children and adults, re-
spectively [16]. In Dar es Salaam, two previous reports
showed that, E. coli accounted for 51.1% of UTI in a sur-
vey done in 2010 [17] whereas as high as 64.0% of hos-
pital- and community-acquired UTI was accounted for
by E. coli in 2004 [18].
Finally, we recently showed that in Moshi, north-eastern
Tanzania, E. coli was one of the most common bacterial
pathogen isolates from a range of clinical manifesta-
tions [1]. Advanced molecular diagnostics such as
whole genome sequencing (WGS) have revealed the
emergence of a fatal diarrhoea-causing E. coli strain
that combines virulence factors (VFs) from two E. coli
strains [4]. The VFs are important properties that do
enable an infectious agent to effectively and efficiently
establish itself on or within its host by enhancing its
potential to cause harm or disease. Some of the fac-
tors include those for host cell adherence, immune
evasion, toxins and protease production for disrupting
host cell pathways and scavenging minerals like iron in
order to increase their survival. Certain E. coli strains have
VFs that been linked to a serious outbreaks in China in
1999, where it caused 177 deaths [19], and in Germany in
2011, where it claimed 54 lives [20].
Molecular typing studies to evaluate E. coli related in-
fections in low and middle-income countries (LMICs)
are rare and little information is available regarding the
specific subtypes causing infections in Tanzania or
whether the high prevalence is due to sporadic infectious
or clonal transmission between patients. The purpose of
this study was to determine the serotypes, antimicrobial
resistance and virulence genes. Further, we carried out a
phylogenetic tree reconstruction to determine related-
ness of E. coli isolated from patients in a tertiary care
hospital in Tanzania using the WGS-based diagnostic
platform installed at KCMC hospital in Moshi, Tanzania.
Methods
Study design, participants and specimen collection
A hospital based prospective cross-sectional study was
conducted at KCMC between August 2013 and August
2015. Part of the study’s methods has been described in
details by Kumburu et al. [1]. KCMC is located in Moshi
municipality, north-eastern Tanzania and serves as a
zonal referral hospital for a catchment area of around 15
million people. The hospital has a bed capacity of 650
with approximately 500 outpatients seeking medical ser-
vices daily. This study was granted ethical approval by
the KCMC Research Ethics Committee and the National
Institute for Medical Research. A written informed con-
sent was obtained from each participant or from parents
or guardians of children before enrolment into the study.
The study involved patients admitted in medical, surgi-
cal and paediatrics wards who were suspected to have
bacterial infection. Specimens collected for bacterial cul-
ture were sputum, wound or pus swab, stool and blood.
Bacteria culture, isolation, and identification were per-
formed according to in-house standard operating proce-
dures and the Clinical and Laboratory Standards
Institute (CLSI) guidelines as described by Kumburu et
al. [1]. Over a 2-year period, 590 samples were collected
without apriori knowledge of the infecting agent. A total
of 377 bacterial strains were isolated, and whole genome
sequenced. A number of isolates from this collection
were randomly selected for antimicrobial susceptibility
testing. A total of 38 E. coli collected sequentially were
included in this study; among which 24 E. coli isolates
had antimicrobial susceptibility results.
Genomic DNA isolation, whole genome sequencing, and
analysis
For all E. coli isolates genomic DNA (gDNA) was purified
and its concentration determined using the Easy-DNA ex-
traction kit (Invitrogen®) and the Qubit dsDNA Assay Kit
(Invitrogen®), respectively. The gDNA library preparation
was performed following Nextera® XT DNA Sample
Preparation Guide [21]. In brief, each gDNA was tagmented
(tagged and fragmented) by the Nextera® XT transposome.
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The transposome simultaneously fragments the input DNA
and adds adapter sequences to the fragment ends. Then
followed a limited-cycle PCR amplification whereby indexes
required for cluster formation were added to each DNA
piece. Then each gDNA library was normalized to ensure
equal representation during sequencing. Equal volumes of
the normalized library were combined, diluted in
hybridization buffer, and heat denatured prior to sequencing
on the Illumina MiSeq platform (Illumina Inc.). The sequen-
cer output was analysed using the standard WGS pipeline at
KCRI, which is based on local implementations of the bio-
informatics services available at https://cge.cbs.dtu.dk/ser-
vices/. Quality control of the reads was performed using
FastQC 0.11.4 [22]. De novo assembly was performed with
SPAdes 3.11.1 [23], and quality assessed using QUAST 4.5
[24]. For this article’s purpose the analyses included: resist-
ance genes identification using ResFinder 2.1 [25],
Multi-Locus Sequence Typing (MLST) determination using
MLST 1.8 [26], serotyping using SeroTypeFinder 1.1 [27],
and virulence genes determination using VirulenceFinder 1.4
[28]. Phylogeny reconstruction was done using CSI Phyl-
ogeny [29] (with reference strain EC958, NZ_HG941718.1).
The 38 assembled E. coli genomes of the present study have
been submitted to the European Nucleotide Archive with
project accession number PRJEB23541. The phylogenetic
analyses included 6 more E. coli genomes previously isolated
from animals in Mwanza, north-western Tanzania, by Seni
et al. [30]. The raw sequence data of the E. coli of animal
origin were downloaded from the European Nucleotide
Archive (ENA) under the project number PRJEB12335. Stata
13 (College Station, Texas 77,845 USA) was used to deter-
mine Cohen’s kappa coefficient of agreement between the
phenotypically tested and whole genome sequence predicted
antimicrobial resistance.
Results
Specimens and isolates
A total of 38 non-duplicate E. coli were isolated, of
which 18 (47.4%) were from wound (or pus) swabs, 13
(34.2%) from diarrhoeal stool, 4 (10.5%) from sputum
and 3 (7.9%) from blood. Twenty-three (60.5%) were
isolated from patients in medical wards, 9 (23.7%) from
patients in surgical wards, and 6 (15.8%) from patients
in intensive care unit (ICU). Out of these six E. coli
isolates, four were from surgical ICU and 2 from med-
ical ICU. Thirteen (34.2%) E. coli were isolated in 2013,
16 (42.1%) in 2014 and nine (23.7%) in 2015 (Table 1).
Multi-locus sequence typing and serotyping
Out of 38 E. coli isolates, 21 different STs were observed.
Eight (21.1%) E. coli belonged to ST131; 3 isolated in
2013, 2 in 2014 and 3 in 2015 (Table 1). Two of the E.
coli ST131 were isolated from patients in surgical wards,
and six from patients in medical wards, including one
from medical ICU. Of these eight, seven (87.5%) E. coli
had serotype O25:H4 and one had serotype O15:H1.
Out of 38 isolates, 10 (18.4%) belonged to ST10 clonal
complex; of these, four (40.0%) were ST617 with sero-
type O89:H10, of which 3 were isolated in 2014 and 1 in
2015 and three (30.0%) were ST10, of which two had
serotype O89:H10 and one had serotype O89:H9
(Table 2). These ST10 were all isolated in 2014 from
medical wards. We noted that, out of the three ST410,
one had serotype O8:H21, and the others had unknown
O-group but belonged to H9.
Virulence factors
Table 2 as well show the distribution of virulence factors
(VFs) among the sequenced E. coli isolates. A total of 22
(57.9%) E. coli isolates carried VFs for host cells adher-
ence. These included 12 (31.6%) for iha, 7 (18.4%) for
lpfA and 6 (15.8%) for each of aafC and nfaE. The preva-
lence of eilA was 3 (7.9%) and 2 (5.3%) for each of eae
and bfpA. A total of 9 (23.7%) E. coli isolates had VFs
that promote toxin production. The distribution of VFs
that promote toxin was 7 (18.4%) for senB and 2 (5.3%)
for each of astA and pic. The VFs that promote E. coli
protease production were detected in 18 (47.4%) E. coli
isolates. The prevalent protease VFs were sat and vat
with 13 (34.2%) and 5 (13.2%), respectively. A total of 25
(65.7%) E. coli isolates had iss, a factor that promotes E.
coli immune evasion by increasing serum survival.
Acquired antimicrobial resistance
A total of 28 (73.7%) E. coli carried genes encoding
beta-lactam resistance enzymes (Table 3). The blaCTX-M-15
was harboured by 17 (44.7%) isolates, blaOXA-1 harboured
by 19 (50%) and blaTEM-1B by 12 (31.6%). The overall pro-
portion of dfrA genes encoding trimethoprim resistance
enzymes was 28 (73.7%). The dfrA17 was the most abun-
dant gene with a proportion of 16 (42.1%) followed by 6
(15%) for dfrA14 genes, and 2 (5.3%) for each of dfrA5,
dfrA7 and dfrA12.
A total of 19 (50%) E. coli carried mph(A), a gene en-
coding macrolide resistance enzymes including towards
erythromycin and azithromycin. The prevalence of genes
encoding sulphonamides resistance enzyme for sul1 and
sul2 were 19 (47.5%) and 24 (60.5%), respectively. The
proportion of genes encoding tetracycline resistance en-
zymes for tet(A) and tet(B) were 16 (42.1%) and 9
(23.7%) respectively. The proportions of genes encoding
chloramphenicol resistance enzymes were 19 (50%) for
catB3 and 3 (7.9%) for catA1. A total of 22 (57.9%) isolates
carried both strA and strB genes against aminoglycoside.
The gene aadA5 was detected in 15 (39.5%), for each
aadA2 and aadA1 in 2 (5.3%) and aadB in 1 (2.6%) E. coli
isolates. Others included aac(3)-IIa in 9 (23.7%) and
aac(3)-IId in 2 (5.3%) of the E. coli isolates.
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Table 1 Origin and drug susceptibility results of 38 clinical E. coli isolates
Origin of isolate Drug susceptibility resultsd
Isolate wardb specimenc yeara AMC AM CZ CAZ CRO C CIP GM NA SXT
4 MW Stool 2013 S R S S S S S S S R
5 MW Stool 2013 S S S S S S S S S S
6 MW Stool 2013 S S S S S S S S S S
10 SW Swab 2013 R R S S S S R S R S
21 MW Stool 2013 R S S S S S S S S R
22 MW Stool 2013 N N N N N N N N N N
30 SW Swab 2013 S S S S S S S S S S
44 SICU Swab 2013 S R R R R S R R R R
70 MW Sputum 2013 R R R R R S R S R R
73 MW Stool 2013 R R R R R S R S R R
82 MW Stool 2013 R R R S R S R S R R
97 MW Stool 2014 N N N N N N N N N N
115 SW Swab 2014 S R R R R S S S S R
199 MW Blood 2014 R R R R R R R R R R
203 MW Stool 2014 R R S S S S R S R R
210 MW Blood 2014 R R R R R S R R R R
244 MW Sputum 2014 R R R R R S R R R R
245 MW Swab 2014 R R R R R S R R R R
247 MW Blood 2014 R R R S R S R S R R
298 MW Stool 2014 N N N N N N N N N N
365 SICU Swab 2014 R R R R R S R S R R
393 MICU Stool 2015 R R R R R S R R R R
521 MW Sputum 2014 S S S S S S S S R R
538 SW Swab 2015 N N N N N N N N N N
554 MW Stool 2015 N N N N N N N N N N
587 SW Swab 2015 N N N N N N N N N N
603 MICU Swab 2015 N N N N N N N N N N
118A SW Swab 2014 S R S S S S S S S S
119EC MW Stool 2014 S S R R R R S S S S
163A SW Swab 2014 S S S S S S S S S S
237C SW Swab 2014 N N N N N N N N N N
340B MW Sputum 2014 S S S S S S S S S R
431D SICU Swab 2015 N N N N N N N N N N
567B SW Swab 2015 N N N N N N N N N N
598A MW Swab 2015 N N N N N N N N N N
598B MW Swab 2015 N N N N N N N N N N
71E MW Swab 2013 R R R R R S R R R R
77E SICU Swab 2013 R R R R R S R S R S
ayear of collection
b MW Medical ward, SW surgical ward, MICU medical ICU, SICU surgical ICU
cWound or pus swab, diarrhoea or stool
d S Susceptible, R Resistant, N Not tested, AMC Amoxicillin-Clavulanate, AM ampicillin, CZ cefazoline, CAZ ceftazidime, CRO ceftriaxone, C chloramphenicol, CIP
ciprofloxacin, GM gentamycin, NA Nalidixic acid, SXT trimethoprim sulphamethoxazole
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Table 2 Sequence types, Serotypes and Virulence factors of 38 clinical E. coli isolates
Isolate STe Serotype Virulence Factors
Adherence Toxin Protease Evasiong Type IIIh
70 ST-131 O25:H4 Iha,nfaE sat iss
73 ST-131 O25:H4 Iha,nfaE sat iss
199 ST-131 O25:H4 Iha astA,senB sat iss
210 ST-131 O25:H4 Iha,nfaE senB sat iss
587 ST-131 O25:H4 Iha sat iss
603 ST-131 O15:H1 iha,nfaE lpfA,eilA senB sat iss air
567B ST-131 O25:H4 Iha sat iss
71E ST-131 O25:H4 iha,nfaE senB sat iss
244 ST-617f O89:H10 iss
245 ST-617 f O89:H10 iss
538 ST-617 f O89:H10 astA,senB iss capU
237C ST-617 f O89:H10 iss
393 ST-405 O102:H6 eilA air
10 ST-410 O??:H9 lpfA
22 ST-410 O??:H9 lpfA
598B ST-410 O8:H21 lpfA iss
97 ST-10 f O89:H10
203 ST-10 f O89:H10
340B ST-10 f O89:H9 iss
44 ST-167 f O89:H21
247 ST-167 f O89:H9 senB iss capU
5a ST-226 O40:H19 bfpA,eae espA,espF,espJ nleB,nleC
6a ST-226 O40:H19 bfpA,eae espA,espF,espJ nleB,nleC
118Ad ST-73 O6:H1 Iha pic sat,vat iss mchB,mchC,mchF,mcmA
21 ST-942 O39:H28 lpfA iss
554c ST-95 O2(50):H4 iss mchF
431D ST-44 f O89:H4
119EC ST-4959 O154:H4
521b ST-504 O166:H7 Iha vat iss mchB,mchC,mchF,mcmA, sigA, capU
4 ST-2332 O128:H45 cfaC, lngA eatA
30 ST-355 O150:H5 pic vat iss
115 ST-361 O9:H30
163A ST-372 O83:H31 vat iss
298 ST-38 O86:H18 Iha,nfaE eilA senB sat iss air
365 ST-224 O8:H23 lpfA iss
82 ST-156 O61:H34 lpfA iss
598A ST-1193 O75:H5 Iha senB sat,vat
77E ST-1284 O89:H21 iss
aHas virulence factor tir
bHas virulence factor iroN
cHas virulence factors ireA,iroN
dHas virulence factor ireA
eSequence Type (ST)
fST-10 clonal complex
gImmune evasion
hType III translocated protein
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Phenotype and sequence based antimicrobial resistance
comparison
Agreement between phenotype and whole genome sequence
based antimicrobial resistance was done for 24 out of 38 E.
coli isolates (Table 4). On average, agreement across all drugs
tested was 83.9%. Overall, the phenotypically determined
resistance was higher than sequence-based resistance.
However, all but trimethoprim sulpha or co-trimoxazole
showed strong agreement (81–100%) between phenotype and
sequence-based resistance results. Trimethoprim/sulphameth-
oxazole (co-trimoxazole) showed moderate agreement: 45.8%,
kappa =15% and p =0.08. Sequence-based analysis predicted
resistance in 4 (16.7%) isolates, whereas phenotypic
testing revealed 17 (70.8%) isolates to be resistant.
Amoxicillin-clavulanate showed strongest agreement:
87.5%, kappa = 74% and p = 0.0001. Sequence-based
analysis predicted resistance to amoxicillin-clavulanate
in 14 (58.3%) isolates, whereas 15 (62.5%) isolates
were found to be resistant phenotypically.
Phylogeny and genome comparison
The observed minimum and maximum SNPs difference
between one isolate and another in a pairwise genome
comparison for ST131 were 234 and 10,425 respectively
(Additional file 1: Table S1). The tree topology for ST131
showed one isolate segregating very distinctly from the
rest (Fig. 1). For ST10 clonal complex the observed
minimum and maximum SNPs difference between one
isolate and another were 157 and 35,103 respectively
(Additional file 2: Table S2). Looking at the tree for ST10
clonal complex (Fig. 2), limited pattern of the E. coli iso-
lates was observed. In this tree, with the exception of
ST617 in the middle clade of the ST10 clonal complex
tree, all other STs making this complex occurred across
the trees with little apparent segregation. Furthermore,
the resistance and virulence genes were spread almost uni-
versally across both phylogenetic trees.
Discussion
The present study revealed a high diversity of E. coli
strains circulating in KCMC hospital settings as mea-
sured by Multi-Locus Sequence Typing and Serotyping.
However, strains belonging to O25:H4-ST131 and
O89:H10-ST617 (ST10 clonal complex) were found to
predominate. These findings are similar to the findings
from other continents describing the spread and pre-
dominance of these endemic clones in health facilities
[31–34]. The observed clonal diversity in this hospital
may suggest sporadic introductions of diverse strains
into the hospital from the community. To explore
whether or not similar STs were clonally related, SNP
difference between isolates and phylogenetic analysis
suggested the existence of multiple clones of E. coli in
these settings. A similar clonal diversity was observed
when STs from the present study were compared to simi-
lar STs of E. coli isolates from companion and other do-
mesticated animals in Mwanza, north western Tanzania.
Overall, levels of antimicrobial resistance in E. coli iso-
lates were observed to be high. Trimethoprim/sulpha-
methoxazole (co-trimoxazole) resistance was observed
to be lower (70%) than the one (93%) found by Seni et
al. [30], but in the present study on average 54–60% re-
sistance to amoxicillin-clavulanate, ampicillin, ceftazi-
dime, ceftriaxone, and ciprofloxacin was higher than
that reported by Seni et al. [30]. Strong agreement (81–
100%) between sequence and phenotype-based resistance
to all drugs tested was observed. However, trimethoprim/
sulphamethoxazole revealed moderate agreement (45.8%)
between the two methods. The phenotypically determined
resistance to trimethoprim/sulphamethoxazole was higher
than sequence-based resistance. The plausible explana-
tions for the observed difference could be that our analysis
used only known resistance genes and did not include
point mutations. Also, resistance in gram negative bacteria
including E. coli is multifactorial and not all genes in-
volved in resistance mechanisms have been uncovered.
Table 4 Agreement between phenotypically tested and whole genome sequence predicted antimicrobial resistance
Antibiotic name DSTa WGSb Agreement Kappa P value
Amoxicillin-Clavulanate 15 (62.5%) 14 (58.3%) 0.875 0.74 0.0001
Ampicillin 16 (66.7%) 14 (58.3%) 0.9167 0.82 0.00
Ceftazidime 13 (54.2%) 13 (54.2%) 0.9167 0.83 0.00
Ceftriaxone 15 (62.5) 13 (54.2%) 0.9167 0.84 0.00
Chloramphenicol 2 (8.3%) 2 (8.3%) 0.8333 −0.09 0.672
Ciprofloxacin 15 (62.5%) 14 (58.3%) 0.875 0.74 0.0001
Gentamycin 7 (29.2%) 7 (29.2%) 0.9167 0.79 0.00
Trimethoprim Sulpha 17 (70.8%) 4 (16.7%) 0.4583 0.15 0.0799
a phenotype-based resistance
b whole genome sequence-based resistance
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Following analysis of resistance genes, over 70% of the
E. coli strains carried genes encoding beta-lactamases,
with blaOXA-1 being predominant (50%) followed by
blaCTX-M-15 (44.7%) and blaTEM-1B (31.6%). The preva-
lence of blaCTX-M-15 found in the present study contrasts
with Manyahi et al. [18] who found blaCTX-M-15 as the
most prevalent gene (90.6%) in a tertiary hospital in Dar
es Salaam. Nonetheless, similar to the present study,
O25:H4-ST131 was reported to be a major cause of
MDR E. coli infections [35]. The proportion (70%) of E.
coli strains carrying genes encoding beta-lactamases,
correlates in this study with a high (50%) presence of
aac(6’)Ib-cr encoding ciprofloxacin resistance enzymes.
Although aac(6’)Ib-cr encodes low level ciprofloxacin re-
sistance by itself (as well as aminoglycoside resistance),
and usually requires additional mutations (e.g. in
chromosomal gyrA or parC) to confer high level resist-
ance, it is a threat to ciprofloxacin which in our settings
is one of the most prescribed drugs. Other studies in the
US [36, 37], Brazil [38] and Korea [34] have documented
similar findings to the present study of the co-carriage
of aac(6’)Ib-cr, ESBL genes and the existence of
ciprofloxacin resistance in E. coli ST131. Further, an
agreement between the presence or absence of
aac(6’)Ib-cr and phenotypic resistance results in particu-
lar ciprofloxacin was noted by Madoshi et al. [39] who
characterised E. coli isolates from healthy cattle and cat-
tle attendants in Morogoro, Tanzania [39]. Among other
fluoroquinolones, ciprofloxacin is one of the most pre-
scribed antibiotics in Tanzania. Plausibly this explains
the observed linkage between ciprofloxacin resistance
and carriage of aac(6’)Ib-cr and CTX-M ESBL [31]. The
linkage between quinolone resistance and sub-lineages
of ST131 has been recently explored by Zakour et al.
[40] whereby this work suggested that quinolone use is
associated with the acquisition of virulence and fluoro-
quinolone resistance determinants and expansion of
clade C2/H30-Rx of quinolone-resistant ST131. Also a
gene (mph(A)) conferring resistance to macrolides in-
cluding erythromycin and azithromycin was detected in
a high proportion. The presence of the mph(A) in E.
coli isolates of the current study was 50%, and thus,
higher than the 13% that was found in E. coli from 5
countries from 4 continents by Nguyen et al. [41].
Fig. 1 Phylogenetic analysis of 10 ST131 E.coli isolates showing serotypes, STs, resistance and virulence genes. KL stands for isolates sampled in
the present study from patients hospitalised at a tertiary hospital in Kilimanjaro. MZ (blue colour) stands for isolates from companion and
domesticated animals in Mwanza. The MZ sequences were downloaded as raw reads from European Nucleotide Archive (ENA) under the project
number PRJEB12335. Number next to KL and MZ is date (year) of sampling or E. coli isolation. CTXM15 stands for blaCTX-M-15, OXA1 for blaOXA-1
and TEM1 for blaTEM-1
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High exposures to erythromycin and azithromycin could
be one possible reason leading to emergence of resistance
to macrolides [42].
Furthermore, the present study noted a high proportion
(73.7%) of dfrA genes encoding trimethoprim resistance
enzymes similar to findings by Madoshi et al. [39] in
Morogoro, Tanzania. Nonetheless, the present study pro-
portion of dfrA genes was relatively higher than that (43%)
found in E. coli isolates from healthy college students in
Ghana and Nigeria in 2005 and 2009 [43]. The observed
proportion difference could be explained by the fact that
resistance in hospital-based studies is relatively higher
than in community-based ones. Another reason could be
that the present study was hospital-based whereas the
West African study population were healthy individuals.
The present study also characterised VFs in all E. coli
isolates. The VFs that facilitate E. coli and host cells or
E. coli and E. coli adherence including long polar fim-
briae (lpfA), adhesin (iha) and intimin (eae) were pre-
dominant among the circulating E. coli O25:H4-ST131
strains. These VFs have been identified as suggestive of
virulent serotypes and may be used as reliable markers
for the identification of pathogenic E. coli [44]. Another
prevalent group of VFs this study noted were those re-
sponsible for E. coli immune evasion by increasing
serum survival (iss). Although the predominance of iss
in the present study was from E. coli isolated from hos-
pitalised patients, in Mwanza north-western Tanzania,
Msahana et al. [45] noted a similar pattern of iss in E.
coli that were community-acquired. In this study we ob-
served no clear correlation or pattern of VFs with the
clinical findings or patient’s outcomes. However, colon-
isation events rather than infections were common as
wound or pus swab and stool specimens constituted the
majority of strains studied. The observed existence of
multiple VFs further underlines the exceptional ability of
E. coli in colonising or causing infections to a wide range
of hosts and niches.
Potential clinical implications for the obtained results
are that caution should be taken when interpreting and
utilising microbiology results especially when E. coli is
isolated in LMICs as most often E. coli is regarded of
low threat. Contrary to that notion, these findings high-
light that E. coli should not be regarded non-pathogenic
until pathogenic and antimicrobial resistance determi-
nants have been truly confirmed absent. Additionally,
the WGS-based findings hint on the existence of noso-
comial transmissions in the hospital thus prompting the
formulation of pragmatic antimicrobial stewardships and
infection prevention and control initiatives.
We understand and acknowledge the limitations of the
present study. First, the analysis was performed on a
Fig. 2 Phylogenetic analysis of 14 ST10 clonal complex (ST10, ST44, ST167, ST617) E.coli isolates showing serotypes, STs, resistance and virulence
genes. KL stands for stands for isolates from patients hospitalised at a tertiary hospital in Kilimanjaro. MZ (blue colour) stands for isolates from
companion and domesticated animals in Mwanza. The MZ sequences were downloaded as raw reads from European Nucleotide Archive (ENA)
under the project number PRJEB12335. Number next to KL and MZ is date (year) of sampling or E. coli isolation. CTXM15 stands for blaCTX-M-15,
OXA1 for blaOXA-1 and TEM1 for blaTEM-1
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small number of E. coli isolates, which may limit gener-
alisation of the findings. With such a small number of
the isolates analysed, it is important to point out that an-
other limitation that this work was likely to suffer from
was the lack of deeper statistical analysis to correlate the
isolates resistance and virulence findings with patients
characteristics (age, gender, ward, room, specimen)
Third, the existence of genes encoding different resist-
ance and virulence factors is only indicative of the genes
present in the isolates. On the other hand, RNA sequen-
cing which is an avenue for future studies could have
given a strong evidence of expression levels of genes en-
coding different resistance and virulence factors.
Conclusion
The observed high levels of E. coli diversity in terms of
their antimicrobial resistance genes, serotypes and viru-
lence genes underlines the necessity for concerted efforts
to routinely screen all bacterial isolates of clinical im-
portance especially in tertiary health care facilities. WGS
use for laboratory-based surveillance can be an effective
early warning system for emerging pathogens and resist-
ance mechanisms in LMICs. The information generated
in this study will not only provide updates on levels of
virulence and antimicrobial resistance at hospital level
but will also be used as a basis in formulating pragmatic
antimicrobial stewardships and infection prevention and
control initiatives.
Additional files
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